Search Results for "estrogen"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for estrogen. Results 61 to 70 of 114 total matches.

Dehydroepiandrosterone (DHEA)

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
of both androgens and estrogens. Plasma concentrations peak at about 20-30 years of age ...
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Med Lett Drugs Ther. 2005 May 9;47(1208):37-8 |  Show IntroductionHide Introduction

Grapefruit Juice Interactions With Drugs

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
Pharmacol Ther, 58:20, July 1995). ESTROGENS — In one study, grapefruit juice inhibited the metabolism ...
In a study of the interaction between alcohol and the calcium-channel blocker felodipine (Plendil), the grapefruit juice vehicle for the alcohol appeared to increase felodipine plasma concentrations. Subsequent studies have found that grapefruit juice increases plasma concentrations of several calcium-channel blockers and of some other drugs as well (DG Bailey et al, Clin Pharmacokinet, 26:91, 1994).
Med Lett Drugs Ther. 1995 Aug 18;37(955):73-4 |  Show IntroductionHide Introduction

Cholesterol-lowering margarine

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999  (Issue 1055)
administration of beta-sitosterol has estrogen-like effects in animals, no estrogenic activity was detected ...
Two cholesterol-lowering margarines have been marketed in the USA.
Med Lett Drugs Ther. 1999 Jun 18;41(1055):56-8 |  Show IntroductionHide Introduction

Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated ...
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others). Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives. They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone and ethinyl estradiol have been available for years.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):18-9 |  Show IntroductionHide Introduction

Drugs for Assisted Reproduction

   
Treatment Guidelines from The Medical Letter • Oct 01, 2003  (Issue 14)
is generally tried first in anovulatory or oligo-ovulatory women with endogenous estrogen activity and normal ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Treat Guidel Med Lett. 2003 Oct;1(14):89-92 |  Show IntroductionHide Introduction

Problems With Dietary Supplements

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002  (Issue 1140)
Department of Health Services had found that PC Spes, an herbal dietary supplement with estrogen-like ...
Millions of people now take herbal products and other "dietary supplements." The Physicians' Desk Reference has published a PDR for Herbal Medicines listing their ingredients and indications, and the Drug Topics Red Book lists their prices.
Med Lett Drugs Ther. 2002 Sep 30;44(1140):84-6 |  Show IntroductionHide Introduction

In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
), hypothyroidism (n=1), and asthma (n=1); one woman was taking estrogen/progesterone.1-3 CVST ...
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1 |  Show IntroductionHide Introduction

Romidepsin (Istodax) for Cutaneous T-Cell Lymphoma

   
The Medical Letter on Drugs and Therapeutics • May 31, 2010  (Issue 1339)
), may decrease them. Romidepsin binds to estrogen receptors and may reduce the efficacy of estrogen-containing ...
The FDA has approved romidepsin (Istodax – Celgene), an IV histone deacetylase (HDAC) inhibitor, for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The most common types of CTCL are mycosis fungoides, a low-grade lymphoma usually confined to the skin, and Sézary syndrome, a more aggressive disease with malignant lymphocytes in the blood. Both can progress to fatal systemic involvement. Romidepsin is the second HDAC inhibitor approved for this indication; vorinostat (Zolinza), an oral HDAC inhibitor, was approved...
Med Lett Drugs Ther. 2010 May 31;52(1339):42-3 |  Show IntroductionHide Introduction

Annovera - A New Contraceptive Vaginal Ring

   
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019  (Issue 1587)
(but not with the Annovera ring to date); a causal relationship has not been established. CONTRAINDICATIONS — Estrogen ...
Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first product to contain segesterone and the second vaginal ring to become available in the US; NuvaRing, which delivers etonogestrel and ethinyl estradiol, was the first. Unlike NuvaRing, which requires use of a new ring each month, the Annovera ring can be used for an entire year, but it must be removed for one week each month.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):197-8 |  Show IntroductionHide Introduction

In Brief: Alternatives to Mifepristone for Medication Abortion

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
inhibitor letrozole inhibits production of estrogen, which has a critical role in early pregnancy ...
The possibility that use of mifepristone (Mifeprex, and generics) may be restricted has led to questions about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3   doi:10.58347/tml.2023.1679d |  Show IntroductionHide Introduction